STANDARD BIOTOOLS INC.

Analyst Reco. Standard BioTools Inc.

Equities

LAB

US34385P1084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
2.48 ^USD	+3.33%		0.00%	+12.22%

May. 08	Transcript : Standard BioTools Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08	Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q1 Revenue $45.5M, vs. Street Est of $46M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Starts Standard BioTools With Buy Rating, $3.50 Price Target	Apr. 16	MT
Jefferies Initiates Coverage on Standard BioTools With Buy Rating, $3.25 Price Target	Apr. 04	MT
KeyBanc Initiates Standard BioTools at Overweight With $4 Price Target, Sees 'Attractively Valued Way to Invest' in Life Sciences Technology	23-07-12	MT
BTIG Adjusts Fluidigm's Price Target to $10 From $12, Reiterates Buy Rating	21-12-16	MT
FLUIDIGM : UBS Adjusts Fluidigm's Price Target to $9 From $10, Reiterates Buy Rating	21-02-11	MT
FLUIDIGM : UBS Adjusts Fluidigm's Price Target to $10 From $15, Citing Lower Revenue Forecasts for COVID Testing Business; Buy Rating Kept	21-01-07	MT
FLUIDIGM : Piper Sandler Adjusts Fluidigm's Price Target to $15 from $12, Maintains Overweight Rating	20-11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW